Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
November 03, 2023 16:15 ET
|
Aridis Pharmaceuticals, Inc.
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) --...
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023 06:30 ET
|
Ocugen
NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routesOCU500 will be tested as both...
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
August 30, 2023 07:32 ET
|
Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
August 24, 2023 16:05 ET
|
Imunon, Inc.
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
June 01, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
April 21, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Metaclipse Therapeutics Awarded Funding from NIAID for COVID-19 Vaccine Development
July 20, 2020 09:00 ET
|
Metaclipse Therapeutics
ATLANTA, July 20, 2020 (GLOBE NEWSWIRE) -- Metaclipse, a late-stage biotechnology company developing next-generation vaccines with a particular focus on treatments for the elderly, has been awarded...
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
July 15, 2020 13:34 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
June 23, 2020 17:21 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...